BridgeBio Oncology officer proposes 78-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics, Inc. officer Marc Cobo reported a proposed sale of 78 common shares, with an approximate sale date of November 13, 2026, and an aggregate market value of $183.30. The shares were acquired from the issuer as restricted stock units on October 1, 2026. The notice lists July 24, 2026 as the date of plan adoption or instruction under Rule 10b5-1.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.